Abstract Number: 2575 • 2012 ACR/ARHP Annual Meeting
Inhibition of Pathogenic Autoantibodies by Accelerating the Exit of Germinal Center B Cells Via Manipulation of Regulator of G-Protein Signaling
Background/Purpose: Regulator of G-protein Signaling (RGS) plays a key role in inhibiting chemokine signaling by desensitizing G-protein coupled receptor signals. RGS13 and RGS16 are two…Abstract Number: 514 • 2012 ACR/ARHP Annual Meeting
Frequencies and Numbers of Circulating IL-10 Producing Regulatory B Cells Are Not Disturbed in Pss-Patients but Correlate Negatively with the EULAR Sjögren Syndrome Disease Activity Score (ESSDAI)
Background/Purpose: Recently, a specific and functionally important subset of regulatory B cells (Breg) that negatively regulate autoimmunity and inflammation has been described. Breg cells exert…Abstract Number: 1756 • 2012 ACR/ARHP Annual Meeting
Peripheral Blood B Cell Subsets and BAFF/APRIL Receptor Expression, Together with Circulating BAFF and APRIL Levels, Are Disturbed in Rheumatoid Arthritis but Not in Ankylosing Spondylitis
Background/Purpose: B cells play a critical role in systemic autoimmune disease and especially rheumatoid arthritis (RA). BAFF and APRIL are involved in B cell activation…Abstract Number: 1760 • 2012 ACR/ARHP Annual Meeting
A Gene Expression Signature to Monitor Depletion of Plasma Cells Following MEDI-551 (anti-CD19) Administration
Background/Purpose: Production of pathogenic autoantibodies by inappropriately self-reactive plasma cells (PC) is a hallmark of autoimmune diseases. MEDI-551 is an anti-CD19 antibody which is expected…Abstract Number: 2668 • 2012 ACR/ARHP Annual Meeting
Interferon and B-Cell Gene Signatures Contribute to Diagnosis of pre-Clinical Rheumatoid Arthritis
Background/Purpose: Diagnosis of the preclinical phase of rheumatoid arthritis (pre-RA) allows timely start of treatment with the potential to prevent disease progression. It is known…Abstract Number: 510 • 2012 ACR/ARHP Annual Meeting
IL-7 and IL-7 Receptor Blockade to Selectively Inhibit TLR7-Induced B Cell Activation in Primary Sjögren’s Syndrome
Background/Purpose: Toll-like receptors (TLRs) are involved in the recognition of nucleic acids (viral, bacterial, and possibly self) and have been implicated in several auto-immune diseases.…Abstract Number: 1755 • 2012 ACR/ARHP Annual Meeting
The Alternative ΔCD20 Transcript Variant Is Not Expressed in B Cells and Synovial Tissue From Patients with Rheumatoid Arthritis
Background/Purpose: determining predictive factors for response to biologics may help to select appropriate treatment in patients with RA. Rituximab (RTX) is a chimeric monoclonal antibody…Abstract Number: 1761 • 2012 ACR/ARHP Annual Meeting
Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Monoclonal Antibody That Co-Engages the B Cell Antigen Receptor and the FcγRIIb Inhibitory Receptor
Background/Purpose: XmAb®5871 is a humanized and Fc-engineered antibody that coengages CD19, part of the B cell receptor (BCR) complex, with the inhibitory receptor FcγRIIb (CD32b).…Abstract Number: 2666 • 2012 ACR/ARHP Annual Meeting
A Link Between B Cells and Bone Erosion in RA: RANKL Production by Memory B Cells
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disorder that often leads to joint damage. Several lines of evidence suggests the role of B cells…Abstract Number: 610 • 2012 ACR/ARHP Annual Meeting
B Lymphocyte Stimulator Levels Are Higher in Caucasian SLE Patients Earlier in Disease Course and Predict Damage Accumulation
Background/Purpose: B Lymphocyte Stimulator(BLyS) plays an important role in the pathogenesis of Systemic Lupus Erythematosus(SLE). Whilst trials of anti BLyS-targeted therapy have shown promise, the optimal…Abstract Number: 1754 • 2012 ACR/ARHP Annual Meeting
Disruption of Dominant B-Cell and Plasma Cell Clones in Rheumatoid Arthritis Synovium by Rituximab Correlates with Treatment Response
Background/Purpose: Autoreactive B lymphocytes are thought to play an important role in rheumatoid arthritis (RA). B-cell depletion therapy by rituximab (RTX) has shown that targeting…Abstract Number: 1759 • 2012 ACR/ARHP Annual Meeting
Expression of Surface APRIL and Its Receptor, TACI, Is Upregulated On B Cells From Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients
Background/Purpose: Autoimmune disease affects more than 23 million Americans. Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) are chronic, systemic B-cell mediated autoimmune diseases. During…Abstract Number: 621 • 2012 ACR/ARHP Annual Meeting
Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide
Prolonged improvement of systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Background/Purpose: We report sustained improvement in 15 patients with corticosteroid dependent SLE…Abstract Number: 1752 • 2012 ACR/ARHP Annual Meeting
Depletion of CD4-Effector Memory T Cells and Clonally Expanded IgG4 Memory B Cells May Explain the Therapeutic Efficacy of Rituximab in IgG4-Related Disease: Studies Using Flow Cytometry and Single-Cell Sequencing
Depletion of CD4-effector memory T cells and clonally expanded IgG4 memory B cells may explain the therapeutic efficacy of rituximab in IgG4-related disease: Studies using…Abstract Number: 1758 • 2012 ACR/ARHP Annual Meeting
Serum BAFF Levels and Relationship with BAFF Binding Receptors in Patients with Rheumatoid Arthritis Relapsing After B Cell Depletion Therapy
Background/Purpose: B-cell-activating-factor (BAFF) coordinates differentiation of B cells into immunoglobulin secreting cells (ISC) by binding to 3 different receptors (BBRs), namely BAFF-R, transmembrane activator and…
ACR Meeting Abstracts